Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
- 10:30 - 11:30
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS02.04 - Defining the Role of Immunotherapy in the Treatment of ES-SCLC
10:55 - 11:05 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.03 - Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
00:00 - 00:00 | Presenter: Ji-Youn Han
- Abstract
Loading...
-
+
P03 - Early Stage/Localized Disease - Clinical Trials in Progress
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease
-
+
P03.03 - MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery
00:00 - 00:00 | Presenter: Solange Peters
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.25 - Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
00:00 - 00:00 | Presenter: Kyung Hwan Kim
- Abstract
Loading...
-
+
P60 - Tumor Biology and Systems Biology - Basic and Translational Science - Immune Bio
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
P60.09 - High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients
00:00 - 00:00 | Presenter: Jiae Koh
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.15 - Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status
00:00 - 00:00 | Presenter: Jiyun Lee
- Abstract
Loading...
-
+
P86 - Targeted Therapy - Clinically Focused - New Target
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P86.12 - Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Nahor Haddish-Berhane
- Abstract
Loading...
-
+
MA04 - Health Policy and the Real World
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Health Services Research/Health Economics
-
+
MA04.06 - Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005)
17:15 - 17:20 | Presenter: Jiyun Lee
- Abstract
Loading...
-
+
OA07 - Immuno-biology and Novel Immunotherapeutics from Bench to Bed
- 10:30 - 11:30
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
OA07.05 - Discussant
10:50 - 10:55 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
-
+
PL04 - A Vision for Clinical Trials in 2020 and Beyond (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PL04.02 - Chair
07:00 - 07:00 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
